OR52A1: A GPCR Molecule Targeted for Therapeutic Effects (G23538)

OR52A1: A GPCR Molecule Targeted for Therapeutic Effects

OR52A1 ( Odorant Receptor HOR3'beta4) is a G protein-coupled receptor (GPCR) that is expressed in the nervous system and play a role in mediating sensory perception, particularly of odor. It is one of the five subfamilies of GPCR, known as the OR52A1 subfamily. OR52A1 is characterized by a long extracellular flap that is involved in the Stickiness of the receptor, which can modulate its function.

OR52A1 is expressed in various tissues of the body, including the brain, sensory neurons, and epithelial cells. It is involved in the perception of pheromones, which are substances produced by other organisms, such as sexual partners. The sense of smell is the ability to recognize and identify the source of a pheromone. OR52A1 is thought to play a crucial role in this process by mediating the rapid and sensitive response of the nervous system to pheromones.

One of the well-known functions of OR52A1 is its role in sexual behavior. Studies have shown that OR52A1 is involved in the neural mechanisms that underlie sexual desire and arousal. OR52A1 is also involved in the modulation of sexual behavior in animals, such as the effects of pheromones on mating and fertility.

OR52A1 has also been shown to play a role in the pathophysiology of various neurological disorders, including anxiety and depression. Studies have shown that OR52A1 is involved in the modulation of neurotransmitter release in response to stress and anxiety, and that its function may be disrupted in these disorders.

Due to its involvement in the perception of pheromones and its potential role in the pathophysiology of various neurological disorders, OR52A1 is a promising drug target. Studies have shown that blocking OR52A1 can have therapeutic effects in a variety of psychiatric and neurological disorders, including anxiety, depression, and neurodegenerative diseases.

One of the potential strategies for targeting OR52A1 is the use of small molecules, such as those that can modulate the activity of OR52A1. These molecules can be applied directly to the cells, or they can be administered to the body through various routes, such as intravascular injections or systemic injections.

Another approach for targeting OR52A1 is the use of antibodies that are designed to specifically recognize and bind to OR52A1. These antibodies can be used to block the activity of OR52A1, either by blocking its catalytic activity or by modulating its stability.

In addition to small molecules and antibodies, other potential approaches for targeting OR52A1 include the use of drugs that can modulate the activity of other proteins that are involved in the pathophysiology of OR52A1-related disorders. For example, drugs that can modulate neurotransmitter release, or that can interfere with the signaling pathways that are involved in OR52A1 function, may be useful in targeting OR52A1.

Overall, OR52A1 is a GPCR that is involved in the perception of pheromones and the modulation of neurotransmission. Its function is thought to be involved in the pathophysiology of various neurological disorders, including anxiety and depression. As a potential drug target, OR52A1 is a promising target for the development of new treatments for these disorders.

Protein Name: Olfactory Receptor Family 52 Subfamily A Member 1

Functions: Odorant receptor

The "OR52A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR52A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1